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Abstract
Background: Platelet to Lymphocyte ratio (PLR) is thought to be associated with a worse outcome in multiple
types of cancer. However, the prognostic significance of PLR has not been investigated in the prostate cancer (PCa)
patients receiving hormonal therapy. The objective of this study was to determine the prognostic value of PLR in
PCa patients treated with androgen deprivation therapy (ADT).
Methods: Two-hundred-ninety prostate cancer patients who had undergone ADT as first-line therapy were
retrospectively analyzed. The blood cell counts were performed at the time of diagnosis. PLR was calculated
as the ratio of platelet count to lymphocyte count. Patients were categorized in two groups using a cut-off
point of 117.58 as calculated by the receiver-operating curve analysis. Correlations between PLR and clinical
characteristics were analyzed. Meanwhile, univariate and multivariate cox regression analyses were performed
to determine the associations of PLR with progression-free survival (PFS), cancer-specific survival (CSS) and
overall survival (OS). Prognostic accuracy was evaluated with the Harrell concordance index.
Results: The differences of age, serum prostate-specific antigen (PSA) level, Gleason score, risk stratification
and incidence of metastasis between low PLR group (<117.58) and high PLR group (≥117.58) were not
statistically significant (p > 0.05). Multivariate analyses identified PLR as an independent prognostic factor for
PFS (hazard ratio (HR) = 1.581, p = 0.013), CSS (HR = 1.768, p = 0.037) and OS (HR = 1.650, p = 0.044). The
addition of PLR to the final model improved predictive accuracy (c-index: 0.747, 0.801 and 0.768) for PFS, CSS
and OS compared with the clinicopathological base model (c-index: 0.730, 0.778 and 0.746), which included
Gleason score and incidence of metastasis.
Conclusions: PLR might play a significant role in the prognosis of PCa patients treated with ADT. Thus, we
recommend adding PLR to traditional prognostic model to improve the predictive accuracy.
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Background
Prostate cancer (PCa) is the most commonly diagnosed
cancer and the second leading cause of cancer death in
men in the United States [1]. Androgen deprivation
therapy (ADT) is the mainstay of therapy for patients
with locally advanced or metastatic PCa or patients with
early-stage disease who are ineligible for local regional
treatments due to health disparity [2].
A growing body of evidence suggests that inflamma-
tion might have a major role in the tumorigenesis and
progression of PCa [3–5]. Low serum neutrophil count
predicts a positive prostate biopsy [6]. The neutrophil to
lymphocyte ratio (NLR) seems to represent an independ-
ent prognostic marker in patients with PCa [7].
Similarly, platelet to lymphocyte ratio (PLR) is also a sys-
temic inflammation-based parameter. Numerous studies
have revealed that high pretreatment PLR independently
predicts poor prognosis in patients with tumors includ-
ing gastric cancer [8], pancreatic cancer [9], ovarian can-
cer [10], colorectal cancer [11], non-small cell lung
cancer [12], hepatocellular carcinoma [13], renal cell
cancer [14], esophageal cancer [15]. Yuksel OH et al.
[16] and Kaynar M et al. [17] reported that PLR could
be used to distinguish benign prostatic hyperplasia and
prostate cancer, in support of its diagnostic value. Lang-
senlehner T et al. [18] showed a significant association
between PLR and prognosis of PCa patients who under-
went radiation therapy. However, whether PLR plays an
important role in the prognosis of PCa treated with
ADT has not been reported.
Platelet and lymphocyte counts are routinely per-
formed in most clinical laboratories worldwide, therefore
we evaluated whether pretreatment PLR could predict
the clinical outcome of PCa patients treated with ADT.
Methods
Study population
After obtaining approval from the Ethics Committee at
the Renji Hospital, Shanghai Jiao Tong University School
of Medicine, and informed consent from patients, med-
ical records of 325 prostate cancer patients who had
undergone ADT as first-line therapy at the Renji Hos-
pital between January 2010 and December 2014 were
retrospectively reviewed. We excluded patients with
coagulation-related diseases, inflammatory diseases,
autoimmune diseases, cerebrovascular diseases, other
types of cancer, and those patients lost to follow-up. We
finally assembled a cohort of 290 prostate cancer pa-
tients who had blood cell counts performed within
2 weeks before prostate biopsy.
Clinical and pathological evaluation
Medical data on clinical characteristics including age,
serum prostate-specific antigen (PSA) level and blood
cell counts at diagnosis, clinical tumor stage, biopsy
Gleason score and follow-up information were collected.
The pathologic slides were re-reviewed by the urologic
pathologists, and the Gleason scores were obtained from
the original pathology reports. For clinical tumor stage,
patients underwent pelvic Computed Tomography (CT)
or Magnetic Resonance Imaging (MRI). Radionuclide
bone scan was performed to determine whether there
was bone metastasis. PCa patients were stratified into
low-, intermediate-, and high-risk groups according to
the EAU guidelines [19]: low-risk group, PSA < 10 μg/L
and Gleason Score <7 and cT1c-2a; intermediate-risk
group, PSA 10–20 μg/L or Gleason Score 7 or cT2b-2c;
and high-risk group, PSA > 20 μg/L or Gleason Score 8–
10 or > cT2c.
Eligible patients were treated with continuous ADT as
first-line therapy, including castration and antiandrogen
therapy. Castration involved surgical or medical castra-
tion by using a luteinizing hormone releasing hormone
(LHRH) agonist, such as goserelin 3.6 mg, administered
subcutaneously every month. Antiandrogen therapy was
by bicalutamide tablets 50 mg per day orally or fluta-
mide 3 times a day, 250 mg each time orally.
Follow-up
Patients were followed for survival information every
3 months. Duration of the follow-up was assessed from
the date of treatment until the last follow-up (June
2015) or death, which was defined as cancer-related or a
different cause. Progression was defined as castration-
resistance or death, and the castration-resistance was
judged according to the EAU guidelines [20]. The me-
dian follow-up duration was 37.0 months (IQR, 24.0–
50.3).
Laboratory assays
Venous blood samples were collected before the prostate
biopsy. Pre-biopsy platelet and lymphocyte counts were
performed as part of routine clinical procedures to ex-
clude coagulation disorders or presence of acute
infection.
Statistical analysis
The Wilcoxon Signed Rank test was used to interrogate
the median with interquartile ranges (IQRs) between
PLR and clinical characteristics, while chi-squared tests
were used for categorical variables. The cut-off value for
the continuous variable PLR was determined by applying
a receiver operating characteristics curve analysis to test
all possible cut-offs that would separate between pa-
tients’ survival and cancer-related death. The survival
distributions, including progression-free survival (PFS),
cancer-specific survival (CSS) and overall survival (OS)
were estimated by the Kaplan–Meier method and
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compared by a log-rank test, and subgroup analyses
were taken according to Gleason score and incidence of
metastasis. PFS was calculated from the date of prostate
biopsy to the date of disease progression or the time of
the last follow-up. The effect of PLR on PFS, CSS and
OS were examined using cox proportional hazard re-
gression models. All variables including PLR with a p
value <0.05 on univariate analyses were entered into
multivariate stepwise cox regression analyses. Hazard ra-
tio (HR) and 95 % confidence interval (CI) were com-
puted. To examine whether PLR can provide additional
prognostic power when combined with basic clinical var-
iables, we built predictive model and calculated the c-
index by integrating clinical variables with PLR using the
R package “survival.” For each core set, we randomly ex-
tracted 20 % samples as the test set to generate a c-
index, and the above procedure was repeated 100 times
to generate 100 c-indexes. Then, we used the Wilcoxon
signed rank test to calculate the p value. All tests were
two-sided. Differences were considered to be statistically
significant if p < 0.05. Statistical analysis was carried out
using SPSS, version 19.0.
Results
Clinical characteristics
The clinical characteristics of the patients are detailed in
Table 1. The median age of the patients was 75 years old
(IQR, 67–79).
Association between PLR and clinical and pathological
characteristics
Based on ROC curve for survival analysis (CSS), the best
cut-off value for PLR was 117.58, and all patients were
divided into either low PLR group (n = 146, 50.34 %) or
high PLR group (n = 144, 49.66 %). The differences of
age, serum PSA level, Gleason score, risk stratification
and incidence of metastasis between low PLR group and
high PLR group were not significant (p > 0.05). (Table 2).
Association between PLR and prognosis of PCa
The median follow-up duration was 37.0 months, out of
290 patients with usable follow-up information, 126
(43.45 %) patients experienced disease progression, and
70 (24.14 %) patients died, including 60 (20.69 %) pa-
tients died of PCa at the end of the last follow-up.
The patients with high PLR had a significantly worse
survival than those with low PLR with regard to PFS,
CSS and OS (Log-rank test, each P < 0.05, Fig. 1). As
shown in Figs. 2 and 3, in the subgroup of patients with
Gleason score >7 or bone metastasis, high PLR group
predicted the worse PFS, CSS and OS (Log-rank test,
each P < 0.01). However in the subgroup of Gleason
score ≤7 or non-metastasis, the prognostic differences of
clinical outcome were not significant between high PLR
Table 2 Clinical characteristics of prostate cancer patients according to PLR
Parameters PLR P-value
<117.58 (n = 146 50.34 %) ≥117.58 (n = 144 49.66 %)
Age (median, interquartile range), years 76 (66–79) 75 (68–80) 0.632
PSA (median, interquartile range), μg/L 100.00 (28.30–170.00) 100.00 (33.05–213.00) 0.625
Gleason Score (≤7/>7) 76/70 68/76 0.410
Metastasis (no/yes) 87/59 72/72 0.100
Risk Stratification (low intermediate/high) 15/131 13/131 0.719
Platelet (median, interquartile range), 109/L 159.50 (134.00–198.00) 201.00 (167.50–238.50) <0.001
Lymphocyte (median, interquartile range), 109/L 1.84 (1.57–2.21) 1.24 (1.02–1.51) <0.001
Abbreviations: PSA, prostate-specific antigen
Table 1 Clinical characteristics of prostate cancer patients
treated with ADT (n = 290)
Parameters No. of patients (%)
Age (median, interquartile range), years 75 (67–79)
PSA (median, interquartile range), μg/L 100.00 (31.13–198.50)
Gleason Score
< 7 36 (12.41)
7 108 (37.24)








Platelet (median, interquartile range), 109/L 181.50 (145.00–215.25)
Lymphocyte (median, interquartile range), 109/L 1.54 (1.21–1.89)
PLR 117.46 (87.26–154.57)
Progression-free survival 126 (43.45)
Cancer-specific survival 60 (20.69)
Overall survival 70 (24.14)
Follow-up time (months) 37.00 (24.00–50.30)
Abbreviations: PSA prostate-specific antigen
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group and low PLR group (Log-rank test, each P > 0.05).
Univariate and multivariate cox regression analyses
(stepwise analysis) of the factors influencing PFS, CSS
and OS were presented in Tables 3 and 4. Univariate
analyses demonstrated that serum PSA level, Gleason
score, incidence of metastasis, PLR were significant
predictors for PFS, CSS and OS (each P < 0.05), but age
and risk stratification were significant predictors for PFS,
not for CSS and OS. In the multivariate analyses, we
identified that age, Gleason score, incidence of metasta-
sis and PLR were independent prognostic factors for
PFS, while Gleason score, incidence of metastasis and
Fig. 2 Kaplan-Meier survival curves stratified by PLR in prostate cancer patients with Gleason score ≤7 (I) and Gleason score >7 (II). a Progression-
free survival (PFS), b Cancer-specific survival (CSS) and c Overall survival (OS)
Fig. 1 Kaplan-Meier curves for survival of prostate cancer patients according to PLR. a Progression-free survival (PFS), b Cancer-specific survival
(CSS) and c Overall survival (OS)
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PLR were independent prognostic factors for CSS and
OS. The HRs of PLR were 1.581 (95 % CI 1.100–2.272)
for PFS, 1.768 (95 % CI 1.036–3.015) for CSS and 1.650
(95 % CI 1.013–2.687) for OS, respectively.
The predictive accuracy was calculated with and with-
out the inclusion of PLR. With the base model, including
the traditional predictor variables of Gleason score and
incidence of metastasis, predictive accuracy for PFS, CSS
and OS was 73.0 % (IQR, 71.1–77.1 %), 77.8 % (IQR,
73.1–81.9 %) and 74.6 % (IQR, 71.8–77.7 %). Our new
integrated model with the addition of PLR, predictive ac-
curacy for PFS, CSS and OS was 74.7 % (IQR, 72.3–
77.8 %), 80.1 % (IQR, 76.7–84.2 %) and 76.8 % (IQR,
73.7–79.9 %), respectively. Notably, our integrated model
showed statistically significantly improved predictive
power compared to the base model (each p < 0.001).
Discussion
Despite recent progress in the identification of genetic
and molecular alterations in prostate cancer (PCa), the
routine prognostic risk assessment of PCa patients cur-
rently relies on traditional clinicopathological prognostic
factors, including Gleason score, clinical tumor stage,
and serum PSA level at the time of diagnosis, which are
used for stratify the patients into the low-, intermediate-,
or high-risk group [19]. The predictive accuracy of this
traditional prognostic model need be further improved
by the incorporation of novel prognostic biomarkers.
The platelet and lymphocyte counts are routinely mea-
sured blood-based parameters. In this large cohort of
PCa patients treated with androgen deprivation therapy
(ADT), we found that pretreatment high platelet to
lymphocyte ratio (PLR) was associated with increased
risk for disease recurrence, cancer specific mortality and
all-cause mortality. These findings remained significant
after adjusting for clinicopathological features, indicating
an independent association of high pretreatment PLR
with adverse outcomes.
An exact explanation for this observation remains un-
clear and is yet to be elucidated. The PLR represents a
marker of inflammation. A high PLR reflects both an el-
evated platelet dependent pro-tumor reaction and a de-
creased lymphocyte mediated anti-tumor immune
response, which may both contribute to cancer progres-
sion and poor outcome. Platelets have been shown to
promote cancer growth and metastasis. For instance,
Fig. 3 Kaplan-Meier survival curves stratified by PLR in prostate cancer patients with non-metastasis (I) and metastasis (II). a Progression-free
survival (PFS), b Cancer-specific survival (CSS) and c Overall survival (OS)
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Boucharaba A et al. [21] showed platelet-derived lyso-
phosphatidic acid was critical for bone metastasis forma-
tion in breast cancer. Dashevsky O et al. [22]
demonstrated platelet-derived microparticles promoted
invasiveness of PCa cells via upregulation of MMP-2
production. Zheng S et al. [23] found, in PCa, fibrinogen
help platelets to adhere to tumor cells, and platelets in
turn promoted more fibrinogen to aggregate around
tumor cells by forming thrombin, and thus protected
tumor cells from natural killer cell cytotoxicity, which
was mediated by β3-integrins. There is considerable evi-
dence that lymphocytes represent the cellular basis of
cancer immunosurveillance, which inhibit tumor cell
proliferation and metastasization [24]. Huang SH et al.
[25] showed pretreatment high circulating lymphocytes
could predict better recurrence-free survival and mar-
ginally better overall survival in HPV+ oropharyngeal
cancer patients. Adams S et al. [26] confirmed tumor
stromal lymphocytic infiltration constituted a robust
prognostic factor in triple-negative breast cancers from
Table 3 Univariate analyses of various clinical parameters in prostate cancer patients
Parameters Progression-Free survival Cancer-Specific survival Overall survival
HR (95 % CI) P-value HR (95 % CI) P-value HR (95 % CI) P-value
Age (years) 0.958 (0.938–0.981) <0.001 0.993 (0.962–1.024) 0.641 1.005 (0.975–1.035) 0.749
PSA (μg/L) 1.003 (1.002–1.004) <0.001 1.003 (1.001–1.005) 0.002 1.002 (1.000–1.004) 0.029
Gleason Score <0.001 <0.001 <0.001
≤ 7 1 1 1
> 7 2.791 (1.921–4.055) 4.710 (2.499–8.878) 4.998 (2.286–6.993)
Metastasis <0.001 <0.001 <0.001
No 1 1 1
Yes 3.447 (2.385–4.984) 5.893 (3.128–11.102) 3.951 (2.331–6.696)
Risk Stratification 0.005 0.058 0.111
Lowintermediate 1 1 1
High 4.128 (1.524–11.182) 6.751 (0.935–48.730) 2.560 (0.805–8.140)
Platelet (109/L) 0.053 0.157 0.121
< 190.50 1 1 1
≥ 190.50 1.414 (0.995–2.003) 1.442 (0.869–2.394) 1.450 (0.907–2.318)
Lymphocyte (109/L) 0.866 (0.632–1.185) 0.367 0.724 (0.454–1.153) 0.174 0.775 (0.506–1.188) 0.242
PLR 0.029 0.014 0.020
< 117.58 1 1 1
≥ 117.58 1.480 (1.040–2.107) 1.948 (1.145–3.312) 1.781 (1.096–2.894)
Abbreviations: HR hazard ratio, CI confidence interval, PSA prostate-specific antigen
Table 4 Multivariate analyses of various clinical parameters in prostate cancer patients
Parameters Progression-Free survival Cancer-Specific survival Overall survival
HR (95 % CI) P-value HR (95 % CI) P-value HR (95 % CI) P-value
Age (years) 0.975 (0.955–0.996) 0.023 — —
PSA (μg/L) 0.093 0.916 0.480
Gleason Score <0.001 <0.001 <0.001
≤ 7 1 1 1
> 7 2.136 (1.454–3.137) 3.378 (1.776–6.428) 3.086 (1.747–5.453)
Metastasis <0.001 <0.001 <0.001
No 1 1 1
Yes 2.830 (1.939–4.131) 4.505 (2.367–8.573) 3.080 (1.799–5.274)
PLR 0.013 0.037 0.044
< 117.58 1 1 1
≥ 117.58 1.581 (1.100–2.272) 1.768 (1.036–3.015) 1.650 (1.013–2.687)
Abbreviations: HR hazard ratio, CI confidence interval, PSA prostate-specific antigen
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two phase III randomized adjuvant breast cancer trials.
However, the differences of tumor features including
age, serum PSA level, Gleason score, risk stratification
and incidence of metastasis between low PLR group
(<117.58) and high PLR group (≥117.58) were not sig-
nificant in our study.
To date, adverse clinical outcomes of many cancers have
been associated with an elevated PLR [8–15]. Zhou X et al.
[27] performed a meta-analysis on the prognostic value of
PLR in various cancers, and found that elevated PLR was a
negative predictor for OS with HR of 1.60 (95 % CI 1.35–
1.90, P < 0.001). Similarly, Templeton AJ et al. [28] con-
ducted a systematic review and showed that a high PLR
was associated with worse OS in various solid tumors.
In contrast to the well-known prognostic value of PLR
in other malignancies, its value in PCa is poorly studied.
Only two studies exist regarding the association of PLR
and PCa outcomes. In 384 patients treated with 3D con-
formal radiotherapy from 1999 to 2007, Langsenlehner T
et al. [18] noted an increased PLR (≥190) was a significant
prognostic factor for poor distant metastases-free survival,
cancer-specific survival and overall survival. Importantly,
intergroup inconsistent neo-adjuvant therapy and poten-
tial confounding factors like inflammatory diseases may
affect their study results. In 2015, Li F et al. [29] evaluated
the relationship between PLR ≥150 and all cause mortality
in 103 PCa patients, and found that PLR was an independ-
ent risk factor of 3-year mortality, However, their analysis
was limited by its relatively small patient population and
intergroup inconsistent therapy.
To the best of our knowledge, our analysis is the first
study of PLR on the prognosis of PCa treated with ADT,
and strikingly our results showed that PLR was an inde-
pendent prognostic factor for PFS, CSS and OS. Com-
paring to previous studies, we made a subgroup analysis
and built a new integrated prognostic model. In sub-
group analysis, we found that high PLR could predict
poor prognosis in the subgroup of patients with Gleason
score >7 or bone metastasis. In the subgroup of Gleason
score ≤7 or non-metastasis, however, PLR was not statis-
tically significantly associated with prognosis, probably
because the percentages of patients who reached the
endpoints (progression, cancer-related death and overall
death) in this subgroup were too small. With the trad-
itional prognostic base model, which includes only Glea-
son score and incidence of metastasis, the predictive
accuracy was 73.0, 77.8 and 74.6 % for PFS, CSS and OS,
respectively. The predictive accuracy was clearly im-
proved by the addition of PLR (74.7, 80.1 and 76.8 %).
There are some limitations to our current study. First,
this was a retrospective investigation. Despite the strict en-
rollment criteria applied, we were unable to completely ex-
clude conditions that might cause inflammatory changes in
PCa. Second, the patient data were collected from a single
institution. Our results need to be validated by prospective
research and patient data from multiple medical centers.
Conclusion
PLR might be a novel prognostic marker in predicting
the clinical outcome for PCa patients treated with ADT.
Thus, we recommend adding PLR to traditional prog-
nostic model to improve the predictive accuracy.
Additional file
Additional file 1: Original data of 290 prostate cancer patients receiving
androgen deprivation therapy. (XLS 70 kb)
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Acknowledgements
We sincerely thank the patients for their participation in this study.
Funding
This study was supported by National Natural Science Foundation of China
(91129725, 81572536), Science and Technology Commission of Shanghai
Municipality (14140901700), Shanghai Municipal Education Commission
(15ZZ058), Key Disciplines Group Construction Project of Pudong Health
Bureau of Shanghai (PWZxq2014-05), the Joint research foundation of
Shanghai Shenkang hospital development center on innovative medical
technology (SHDC12015125), Shanghai Municipal Education Commission-
Gaofeng Clinical Medicine Grant Support (20152215), and the Shanghai Jiao
Tong University School of Medicine Translational Research Innovation Fund
(15ZH4002). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Availability of data and materials
You can see the data and materials in Additional file 1 named “original data.xls”.
Authors’ contributions
WYQ, DBJ and XW were responsible for the design of the study. WYQ, XF
and HYR contributed to the manuscript composition, submission and
revision. PJH, ZYJ, SXG, SJJ and LQ participated in the data collection,
interpretation and discussion. WZZ and CY participated in the data analysis
and manuscript mapping. DBJ, XW and HYR was responsible for the funding
application and the supervision and management of the project. All authors
have contributed to and approved the final manuscript.
Competing interest
The authors declare that they have no competing interests.
Consent to publish
We had obtained the consents to publish from the participants to
report individual patients’ data in any form (including images, videos,
voice recordings etc.).
Ethics, consent and permissions
The study was approved by the Ethical Committee of Renji Hospital,
Shanghai Jiao Tong University School of Medicine. Consents to participate in
the study from the participants were obtained.
Author details
1Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao
Tong University, 1630 Dongfang Road, Pudong District, Shanghai 200127,
People’s Republic of China. 2School of Public Health, Shanghai Jiao Tong
University, Shanghai, China. 3Department of Pathology, Renji Hospital, School
of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Wang et al. BMC Cancer  (2016) 16:329 Page 7 of 8
Received: 28 December 2015 Accepted: 16 May 2016
References
1. Siegel R, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;
65(1):5–29.
2. Wein AJ, Kavaussi LR, Novick AC, Partin AW, Peters CA, Nelson JB, et al.
Campbell-Wash urology. 10th ed. Philadelphia: Elsevier; 2012. p. 2934–53.
3. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F,
et al. The controversial relationship between benign prostatic hyperplasia
and prostate cancer: the role of inflammation. Eur Urol. 2011;60(1):106–17.
4. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence.
Histopathology. 2012;60(1):199–215.
5. Taverna G, Pedretti E, Di Caro G, Borroni EM, Marchesi F, Grizzi F. Inflammation
and prostate cancer: friends or foe? Inflamm Res. 2015;64(5):275–86.
6. Fujita K, Imamura R, Tanigawa G, Nakagawa M, Hayashi T, Kishimoto N, et al.
Low serum neutrophil count predicts a positive prostate biopsy. Prostate
Cancer Prostatic Dis. 2012;15(4):386–90.
7. Langsenlehner T, Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T,
Gerger A, et al. Validation of the neutrophil‑to lymphocyte ratio as a
prognostic factor in a cohort of European prostate cancer patients. World J
Urol. 2015 Jan 24. [Epub ahead of print]
8. Wang DS, Ren C, Qiu MZ, Luo HY, Wang ZQ, Zhang DS, et al. Comparison
of the prognostic value of various preoperative inflammation-based factors
in patients with stage III gastric cancer. Tumour Biol. 2012;33(3):749–56.
9. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, et al. Increased
neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary
operable and inoperable pancreatic cancer. Br J Cancer. 2013;109(2):416–21.
10. Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as
an independent prognostic marker in ovarian cancer. Clin Transl Oncol.
2011;13(7):499–503.
11. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, et al. Clinical significance
of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in
patients with operable colorectal cancer. Biomarkers. 2012;17(3):216–22.
12. Liu H, Wu Y, Wang Z, Yao Y, Chen F, Zhang H, et al. Pretreatment platelet-
to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-
based chemotherapy and prognosis for patients with non-small cell lung
cancer. J Thorac Dis. 2013;5(6):783–9.
13. Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, et al. A
novel and validated prognostic index in hepatocellular carcinoma: the
inflammation based index (IBI). J Hepatol. 2012;57(5):1013–20.
14. Fox P, Hudson M, Brown C, Lord S, Gebski V, De Souza P, et al. Markers of
systemic inflammation predict survival in patients with advanced renal cell
cancer. Br J Cancer. 2013;109(1):147–53.
15. Dutta S, Crumley AB, Fullarton GM, Horgan PG, McMillan DC. Comparison of
the prognostic value of tumour- and patient-related factors in patients
undergoing potentially curative resection of esophageal cancer. World J Surg.
2011;35(8):1861–6.
16. Kaynar M, Yildirim ME, Gul M, Kilic O, Ceylan K, Goktas S. Benign prostatic
hyperplasia and prostate cancer differentiation via platelet to lymphocyte
ratio. Cancer Biomark. 2015;15(3):317–23.
17. Yuksel OH, Urkmez A, Akan S, Yldirim C, Verit A. Predictive value of the
platelet-to-lymphocyte ratio in diagnosis of prostate cancer. Asian Pac J
Cancer Prev. 2015;16(15):6407–12.
18. Langsenlehner T, Pichler M, Thurner EM, Krenn-Pilko S, Stojakovic T, Gerger
A, et al. Evaluation of the platelet-to-lymphocyte ratio as a prognostic
indicator in a European cohort of patients with prostate cancer treated with
radiotherapy. Urol Oncol. 2015;33(5):201.e9-16.
19. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al.
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local
treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–37.
20. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al.
EAU guidelines on prostate cancer. part II: Treatment of advanced, relapsing,
and castration-resistant prostatecancer. Eur Urol. 2014;65(2):467–79.
21. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, et al.
Platelet-derived lysophosphatidic acid supports the progression of osteolytic
bone metastases in breast cancer. J Clin Invest. 2004;114(12):1714–25.
22. Dashevsky O, Varon D, Brill A. Platelet-derived microparticles promote
invasiveness of prostate cancer cells via upregulation of MMP-2 production.
Int J Cancer. 2009;124(8):1773–7.
23. Zheng S, Shen J, Jiao Y, Liu Y, Zhang C, Wei M, et al. Platelets and fibeinogen
facilitate each other in protecting tumor cells from natural killer cytotoxicity.
Cancer Sci. 2009;100(5):859–65.
24. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer
immunosurveillance and immunoediting. Immunity. 2004;21(2):137–48.
25. Huang SH, Waldron JN, Milosevic M, Shen X, Ringash J, Su J, et al. Prognostic
value of pretreatment circulating neutrophils, monocytes, and lymphocytes in
oropharyngeal cancer stratified by human papillomavirus status. Cancer. 2015;
121(4):545–55.
26. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al.
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast
cancers from two phase III randomized adjuvant breast cancer trials: ECOG
2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959–66.
27. Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLR
in various cancers: a meta-analysis. PLoS One. 2014;9(6), e101119.
28. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns
T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a
systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;
23(7):1204–12.
29. Li F, Hu HB, Gu S, Chen X, Sun Q. Platelet to lymphocyte ratio plays an
important role in prostate cancer’s diagnosis and prognosis. Int J Clin Exp
Med. 2015;8(7):11746–51.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wang et al. BMC Cancer  (2016) 16:329 Page 8 of 8
